Figure 1.

Time-to-event curves through 1-year for selected adverse events according to CYP2C19 variant. (A) Primary endpoint (myocardial infarction and death). (B) All-cause death. (C) Cardiac death. (D) Major bleeding (BARC≥3). PM, poor metabolizer; NM, normal metabolizer; IM, intermediate metabolizer.